Last reviewed · How we verify
Avelumab first-line maintenance
Avelumab is a human monoclonal antibody that blocks PD-L1, releasing immune cells from tumor-induced suppression to attack cancer cells.
Avelumab is a human monoclonal antibody that blocks PD-L1, releasing immune cells from tumor-induced suppression to attack cancer cells. Used for First-line maintenance treatment of advanced urothelial carcinoma, First-line maintenance treatment of advanced non-small cell lung cancer (NSCLC).
At a glance
| Generic name | Avelumab first-line maintenance |
|---|---|
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Avelumab binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing interaction with PD-1 on T cells. This blockade restores T-cell activation, proliferation, and anti-tumor immunity. In first-line maintenance, it sustains immune response after initial chemotherapy to prevent disease progression.
Approved indications
- First-line maintenance treatment of advanced urothelial carcinoma
- First-line maintenance treatment of advanced non-small cell lung cancer (NSCLC)
Common side effects
- Fatigue
- Infusion-related reactions
- Nausea
- Immune-mediated pneumonitis
- Immune-mediated hepatitis
- Diarrhea
Key clinical trials
- Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (PHASE3)
- JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
- Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma (PHASE2)
- A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) (PHASE2)
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (PHASE2)
- Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.
- Impact of Circadian Rhythm on Immunotherapy (PHASE2)
- A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: